Research
Hormonal
Dual incretin agonists (GLP-1/GIP) such as tirzepatide demonstrate superior weight loss efficacy compared to single GLP-1 agonists.
Tirzepatide (15mg weekly) is a dual-acting drug (GLP-1/GIP) that produces greater weight loss (~21%) than single-acting GLP-1 drugs. It is currently approved for type 2 diabetes and under review for obesity. It requires weekly injection and medical supervision.
StrongSupportsHIGH confidence
Tirzepatide... was efficacious in ameliorating glycaemic control... and body weight... significant weight loss even reaching 20.9% mean change in body weight... with the 15 mg dose of tirzepatide
Why this rating
Based on multiple systematic reviews and large RCTs cited.
Source
Newer pharmacological interventions directed at gut hormones for obesity
Michael Camilleri et al. · British Journal of Pharmacology · 2023
DOI 10.1111/bph.16278
narrative_reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide) produce significant weight loss in adults with obesity, primarily through central appetite suppression and delayed gastric emptying, with efficacy varying by specific agent and dose.Strong
- Delayed gastric emptying contributes to weight loss with GLP-1 agonists, but central appetite suppression is the predominant mechanism.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →